Loading
A phase 3 trial of Pomalidomide, Dexamethasone, Venetoclax in multiple myeloma, run by AbbVie, active and no longer recruiting.
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. is a phase 3 interventional study registered as NCT03539744 by AbbVie, with 265 participants enrolled, started 2018-10-22 and due to reach its primary completion in 2026-08. Interventions recorded: Pomalidomide, Dexamethasone, Venetoclax. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Dexamethasone.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, BCL-2 inhibitors, Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares BCL-2 inhibitors, Relapsed or refractory multiple myeloma, Venetoclax, Multiple myeloma.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.